Phase i and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer

Targeted Oncology

Volumn 3, Issue 1, 2008, Pages 3-11

  Schilsky, Richard L ^a   Geary, David ^a   Skoog, Linda ^a   Desai, Apurva A ^a   Valickas, Joyce ^b   Chen, Bee Lian ^b   Masson, Eric ^b   Laurent, Dirk ^c   Pendowski, Cynthia ^b   Vokes, Everett E ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; Capecitabine; Phase I; Vascular endothelial growth factor receptor; Vatalanib

Indexed keywords

EID: 38349187862     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-007-0070-5     Document Type: Article

References (23)

1. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
2. Sandler A, Gray R, Perry M et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355(24):2542-2550
3. Miller KD, Wang M, Gralow J et al (2005) E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 2005 Annual Meeting (abstract)
4. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134
5. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434
6. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027
7. Wood JM, Bold G, Buchdunger E et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189
8. Drevs J, Hofmann I, Hugenschmidt H et al (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824
9. Solorzano CC, Baker CH, Bruns CJ et al (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16(5):359-370
10. Kim S, Yazici YD, Barber SE et al (2006) Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK 7787/ZK 222584 and CPT-11. Head Neck 28(5):389-399
11. Thomas AL, Morgan B, Horsfield MA et al (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23(18):4162-4171
12. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21(21):3955-3964
13. Roboz GJ, Giles FJ, List AF et al (2006) Phase I study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20:952-957
14. Scott EN, Meinhardt G, Jacques C et al (2007) Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 16:367-379
15. PTK787/ZK222584 Investigator Brochure
16. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097-4106
17. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19(8):2282-2292
18. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20(12):2812-2823
19. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85-104
20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Instit 92:205-216
21. Hecht JR, Trarbach T, Jaeger E et al (2005) A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23(16S, I):3
22. Koehne C, Bajetta E, Lin E et al (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (Vatalanib) or placebo (CONFIRM-2). J Clin Oncol 2006 ASCO Annual Meeting Proceedings 24(18S):3508
23. Jost LM, Gschwind H-P, Jalava T et al (2006) Metabolism and disposition of vatalanib (PTK787/ZK 222584) in cancer patients. Drug Metab Dispos 34(11):1817-1828